These clinical trials demonstrated low-level toxicities due to non-specific uptake of the toxin conjugate in liver and kidneys, but no severe, irreversible adverse events attributable to “on-target, off-tumor” activity, demonstrating the tolerability of targeting such a widely expressed T cell marker and suggested that CD5 CART could be used to safely target T-cell malignancies. This evidence concerns the gene CD5 and neoplasm.